ClinicalTrials.gg
Not yet recruitingNCT06652412Updated Oct 28, 2024

CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC

A Phase 2 interventional study of Ultrafractionated RT and CGA Guided systemic treatment. and data prospectively collected in Colon Cancer and Rectal Cancer, sponsored by Fudan University. Not yet recruiting. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-10-28.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Non-randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Colonic Neoplasms by Fudan University — 11 open to participants now, 12 under way, 3 of them phase 3. Colonic Neoplasms · Fudan University.

Planned enrollment
8th of 16
124 · median 122
Started
2024
with 2 others
Phase 2
10 of 19
7 open now
Primary completion
2027-11
later than 7 of 11 live
Registered
12th of 19
by date

Among the 19 studies in Colonic Neoplasms by Fudan University, this one is the 8th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2024, is one of 10 in phase 2, reaches primary completion later than 7 of the 11 other live ones, and was the 12th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

11 of the 19 studies in Colonic Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Colonic Neoplasms by Fudan University, or all of them as a file.
02

Study summary

This is a prospective, multicentre, cohort study. For cohort 1, experimental cohort, older or Frail patients with inoperable localized colorectal cancer will receive Ultrafractionated Radiotherapy (RT) and Comprehensive Geriatric Assessment (CGA) Guided systemic treatment. All patients will receive Ultrafractionated RT and PD-1 antibody. Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, and BSC.

For cohort 2, external control from real word, data of patients with the same baseline characteristics from the same period and the same institute will be prospectively collected.

The primary endpoint is complete response (CR, pathological complete response [pCR] plus clinical complete response [cCR]) rate. The secondary endpoints include the grade 3-4 acute adverse effects rate, anal preservation rate, survival etc.

Read the detailed description

This is a prospective, multicentre, cohort study. For cohort 1, experimental cohort, older or Frail patients with inoperable localized colorectal cancer will receive Ultrafractionated Radiotherapy (RT) and Comprehensive Geriatric Assessment (CGA) Guided systemic treatment. All patients will receive Ultrafractionated RT and PD-1 antibody. Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, and BSC.

For cohort 2, external control from real word, data of patients with the same baseline characteristics from the same period and the same institute will be prospectively collected.

The primary endpoint is complete response (CR, pathological complete response [pCR] plus clinical complete response [cCR]) rate. The secondary endpoints include the grade 3-4 acute adverse effects rate, anal preservation rate, 1-year DFS rate, 1-year DSS rate, 1-year OS rate etc.

03

Conditions studied

  • Colon Cancer
  • Rectal Cancer
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥70y, or, ≥60 and \<70y but ≥2;
  2. male or female;
  3. confirmed Colorectal adenocarcinoma;
  4. any distance from anal verge;
  5. Clinical stage ≥T2 and/or N+, without distance ;
  6. refuse radical operation, physiologically or technically inoperable;
  7. No previous radiotherapy in the same field;
  8. No chemotherapy prior to enrollment;
  9. No immunotherapy prior to enrollment;
  10. With good compliance during the study
  11. Signed written

Exclusion criteria

Exclusion Criteria:

  1. Known history of other within 3 years,except cured skin cancer, cervical cancer in situ or thyroid carcinoma.
  2. Individuals with a history of uncontrolled epilepsy, central nervous system disease, or psychiatric disorders that, in the judgment of the investigator, are of such clinical severity that they may prevent the signing of an form or affect the patient's adherence to oral medications
  3. Individuals with clinically serious (i.e., active) heart disease, such as symptomatic coronary artery disease, (NYHA) class II or worse congestive heart failure or severe arrhythmia requiring pharmacologic intervention, or history of myocardial infarction within the last 12 months
  4. Individuals with a history of organ transplantation requiring therapy and long-term hormone therapy
  5. Individuals with diseases
  6. Individuals with severe uncontrolled recurrent infections, or other severe uncontrolled concomitant diseases
  7. Baseline hematology and biochemistry did not meet the following criteria: ≥90g/L; NEU ≥1.5×109/L; ≥100×109/L; , AST ≤2.5 times the ; ALP ≤2.5 times the upper limit of normal; TB \<1.5 times the upper limit of normal; Cr \<1 time the upper limit of normal; Alb ≥30g/L
  8. Individuals allergic to any drug component of the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    CGA cohort

    in cohort 1, all patients will receive Ultrafractionated RT, PD-1 antibody, and Comprehensive Geriatric Assessment (CGA) Guided systemic treatment. Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive single agent chemotherapy and BSC; Fit patients will receive doublet chemotherapy and BSC.

    Drug: Ultrafractionated RT and CGA Guided systemic treatment. · Radiation: Ultrafractionated Radiotherapy · Drug: Sintilimab · Drug: Fluorouracil · Drug: Raltitrexed · Drug: Oxaliplatin · Drug: Irinotecan (CPT-11)

  • Other
    external control cohort

    external control from real word, data of patients with the same baseline characteristics from the same period and the same institute will be prospectively collected.

    Other: data prospectively collected

Interventions

  • DrugUltrafractionated RT and CGA Guided systemic treatment.

    in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, and BSC.

  • Otherdata prospectively collected

    in cohort 2, external control from real word, data of patients with the same baseline characteristics from the same period and the same institute will be prospectively collected.

  • RadiationUltrafractionated Radiotherapy

    1Fx every 3 or 4weeks

  • 200 mg q3w

  • 5-Fluorouracil or capecitabine

  • Raltitrexed

  • Oxaliplatin

  • DrugIrinotecanStudies of IrinotecanIrinotecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    irinotecan

06

What researchers measure

Primary outcomes

  1. Complete response (CR) rate

    Rate of complete response (CR), including the rate of pathologic complete response (pCR) after surgery and the rate of clinical complete response (cCR) with Watch \& Wait (W\&W) strategy.

    Time frame: 1 month after the surgery or the decision of W&W

Secondary outcomes

  1. Grade 3-4 adverse effects rate

    Rate of chemotherapy, radiotherapy and immunotherapy related adverse events

    Time frame: From date of randomization until 3 months after the completion neoadjuvant therapy

  2. 1 year anal preservation rate

    1 year anal preservation rate

    Time frame: From date of randomization until the date of or date of death from any cause, whichever came first, assessed up to 12 months.

  3. health-related quality of life (HRQOL)

    HRQOL assessed with validated European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ColoRectal cancer (CR) with 29 items (C29) and with 30 items (C30). Multiple measurements and scores will be aggregated to arrive at one reported value. Scores at different time points after randomization will be compared to baseline scores.

    Time frame: baseline, and at 3, 6 and 12 months.

  4. 1 year disease free survival rate

    Rate of 1 year disease free survival

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.

  5. 1 year local recurrence free survival rate

    Rate of 1 year local recurrence free survival

    Time frame: From date of randomization until the date of first documented pelvic failure, assessed up to 12 months.

  6. 1 year Disease-specific survival rate

    rate of 1 year Disease-specific survival

    Time frame: From date of randomization until the date of death from the specific disease, assessed up to 12 months.

  7. 1 year overall survival rate

    Rate of 1 year overall survival

    Time frame: From date of randomization until the date of death from any cause, assessed up to 12 months.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2024; primary completion for Nov 2027, 36 months later.

Of 123 non-industry phase 2 interventional studies under Colonic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 36 months is below that.

Counting every sponsor, half of 136 studies reached it within 43 months; a quarter within 30 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2024
First posted
Oct 22, 2024
StartEst.
Nov 2024
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2028
Last update
Oct 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06652412
Lead sponsor
Fudan University
Responsible party
Zhen Zhang (Principal Investigator, Fudan University) — Principal investigator
First posted
Oct 22, 2024
Start date
Nov 2024 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Nov 2028 (estimated)
Last update
Oct 28, 2024

Study contacts

Zhen ZHANG Principal Investigator
Contact
zhen_zhang@fudan.edu.cn
18801735029
Yan WANG sub-Investigator
Contact
11111230025@fudan.edu.cn
18121298388
Zhen ZHANG Principal Investigator
principal investigator · Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sintilimab · Raltitrexed

Start the discussion